Sign in
Active, not recruitingPhase 2

Phase II Clinical Trial Evaluating the Efficacy and Safety of HRS-7249 and SHR-1918 in Patients With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis

Key facts

Who runs it
Fujian Shengdi Pharmaceutical Co., Ltd.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
Phase
Phase 2
People taking part
119 people enrolled
Started
25 Feb 2026
Expected to end
Jun 2027
Type of study
Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • HRS-7249 injection set
  • SHR-1918 injection set
  • HRS-7249 injection placebo set
  • SHR-1918 injection placebo set
Record updated
8 September 2026

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (32)Hide the full registry criteria

Who can take part

  • Understand the research procedures and methods, voluntarily participate in this trial, and sign the informed consent form in writing
  • Male or female aged ≥18 years and <80 years on the day of signing the informed consent form

Who cannot take part

  • History of gallstones at the time of screening or previously (except for patients who had their gallbladder removed more than 3 months ago)
  • Acute pancreatitis that has clinically recovered ≤4 weeks before screening or randomization
  • Acute coronary syndrome (such as myocardial infarction, unstable angina), history of coronary artery bypass grafting, percutaneous coronary intervention, peripheral artery revascularization, cerebrovascular diseases (such as stroke, transient ischemic attack), heart failure hospitalization, etc., within 3 months before screening or randomization
  • Severe arrhythmias within 3 months before screening or randomization, such as recurrent symptomatic frequent ventricular premature beats, ventricular tachycardia, atrial fibrillation with rapid ventricular rate
  • Severe infection within 3 months before screening
  • Serious trauma or major surgery within 6 months before screening, or planning major surgery during the trial
  • Plasma exchange therapy within 4 weeks before screening or randomization, or planned during the trial
  • Use of other drugs significantly affecting lipid levels within 4 weeks before screening or randomization, or planned during the trial, such as traditional Chinese medicine containing statins (e.g., Zhibituo, Zhibitai), other lipid-lowering drugs and supplements (e.g., probucol, bile acid sequestrants, niacin, over-the-counter drugs, red yeast rice), GLP-1 agonists, other incretin analogues
  • Use of weight-loss drugs or undergoing weight-altering surgery within 2 months before screening or randomization, or planned during the study
  • History of drug abuse or alcohol abuse (including heavy drinking [average ethanol intake >80 g/day], previously diagnosed alcohol harmful use, alcohol dependence, alcohol poisoning, alcohol withdrawal, alcohol-related disorder, or alcohol-induced psychiatric or behavioral disorder)
  • Significant lifestyle changes within 4 weeks before screening or randomization, or refusal to follow lifestyle guidance or limit alcohol intake to <30 g/day during the study
  • Participation in any interventional drug clinical trial within 3 months prior to screening (participation is defined as administration of the investigational product to the subject), or still within 5 half-lives of the investigational product before screening, whichever is longer; previous participation in non-interventional clinical trials or device-related clinical trials may be judged by the investigator for inclusion
  • Women of childbearing potential who have not used contraception within 30 days prior to screening; women of childbearing potential and male subjects with partners of childbearing age who refuse to avoid donating sperm/eggs from the time of signing the informed consent until the end of the follow-up period, or refuse to comply with relevant contraceptive requirements
  • Malignant tumor within 5 years before screening or randomization (except for non-melanoma skin cancer or cervical carcinoma in situ that has been radically treated)
  • Grade 3/4 heart failure at the time of screening or before randomization
  • History or presence of nephrotic syndrome, severe liver disease, Cushing's syndrome, or other diseases significantly affecting lipid levels at screening
  • Poorly controlled hypertension at screening or before randomization (systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg)
  • Unstable or severe liver, kidney, cardiovascular, psychiatric, neurological, endocrine, hematologic, or other diseases at screening or before randomization, where the investigator determines participation poses an unacceptable risk to the subject
  • Confirmed active syphilis, positive test result for human immunodeficiency virus antibody (HIV-Ab) or hepatitis C virus antibody (HCV-Ab), positive hepatitis B surface antigen (HBsAg) with HBV-DNA ≥1000 copies/ml (or ≥200 IU/ml, or if the detection lower limit is higher than 1000 copies/ml or 200 IU/ml, HBV-DNA ≥ detection lower limit)
  • Other conditions deemed by the investigator to make the subject unsuitable for participation in the trial
  • Diabetes with any of the following: a. Newly diagnosed within 12 weeks before screening or randomization; b. HbA1c ≥8.0% at screening; c. Type 1 diabetes
  • eGFR calculated by the Modification of Diet in Renal Disease (MDRD) formula <60 mL/min/1.73 m²
  • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥3 times the upper limit of normal (ULN)
  • Total bilirubin or direct bilirubin ≥2 times ULN
  • Creatine kinase (CK) >1.5 times ULN
  • Platelet count <100 x 10⁹/L (or history of thrombocytopenia)
  • Hemoglobin <60 g/L
  • Thyroid-stimulating hormone (TSH) below the lower limit of normal (LLN) or above 1.5 times ULN
  • History or presence of hyperthyroidism or hypothyroidism at screening
  • Pregnant or breastfeeding women

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Phase II clinical trial evaluating the efficacy and safety of HRS-7249 and SHR-1918 in patients with severe hypertriglyceridemia at high risk of acute pancreatitis

The 4 groups in the trial

  • HRS-7249 injectionTreatment being tested

    Treatment: HRS-7249 injection set

  • HRS-7249 injection placeboPlacebo, for comparison

    Treatment: HRS-7249 injection placebo set

  • SHR-1918 injectionTreatment being tested

    Treatment: SHR-1918 injection set

  • SHR-1918 injection placeboPlacebo, for comparison

    Treatment: SHR-1918 injection placebo set

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial Evaluating the Efficacy and Safety of HRS-7249 and SHR-1918 in Patients With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis.
Record updated
8 September 2026